We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Protein That Suppresses Invadopodia Formation Prevents Spread of Breast Cancer Cells

By LabMedica International staff writers
Posted on 17 May 2011
Elevated activity of the adaptor protein Cdc42-interacting protein 4 (CIP4) has been found to suppress the formation of invadopodia, actin-rich membrane protrusions that promote extracellular matrix (ECM) degradation and invasiveness of tumor cells.

Investigators at Queen's University (Kingston, ON, Canada) demonstrated the role of CIP4 by using RNA interference technology to block its activity in cultures of breast tumor cells.

They reported in the May 15, 2011, issue of the Journal of Cell Science that these CIP4 "knockdown” cells degraded more ECM, had increased numbers of mature invadopodia, and were more invasive through matrigel. More...
The inhibitory role of CIP4 was explained by the finding that CIP4 limited surface expression of transmembrane type I matrix metalloprotease (MT1-MMP), by promoting MT1-MMP internalization. By removing this enzyme complex from the cell surface CIP4 suppressed invadopodia formation and reduced the ability of the cancer cells to metastasize.

"Cancer researchers want to design new therapeutic strategies in which the metastasis or spreading stage of cancer can be blocked,” explained senior author Dr. Andrew Craig, professor of biochemistry and cancer research at Queen's University. "Patients stand a much better chance of survival if the primary tumor is the only tumor that needs to be treated.”

Related Links:
Queen's University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Clinical Informatics Platform
CLARION™
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.